NextCell's cell therapy manufacturing experience highlighted at BIO-Europe 2026

NextCell Pharma AB announces that its Chief Scientific Officer, Dr Lindsay Davies, has been invited to present at BIO-Europe 2026 in Cologne, Germany. Her presentation will address the challenges of taking allogeneic cell therapies from clinical development to commercial production. The conference programme specifically highlights NextCell's experience in developing manufacturing processes for commercial production.

BIO-Europe, taking place on 9–11 November, is Europe's largest partnering conference for the biotechnology and pharmaceutical industries. The event brings together companies and investors from around the world to establish partnerships and explore new business opportunities.

On 10 November, Lindsay Davies will deliver her presentation on the conference's *Biomanufacturing Strategy Stage*, entitled *Future-proofing Manufacturing for Commercialization of Allogeneic Cell Therapies: From Phase II to Global Commercialization*. She will address key considerations for commercial production, including scale-up, technology transfer, process validation and regulatory requirements.

The presentation draws on NextCell's experience in manufacturing, process development and quality control gained through the development of its NXTCL cell therapy platform.

Lindsay Davies is also Vice President-Elect for Europe at the International Society for Cell & Gene Therapy (ISCT).

Read more about Lindsay's participation at BIO-Europe 2026:
https://informaconnect.com/bioeurope/speakers/lindsay-davies/

For more information, please contact:

Mathias Svahn, CEO
Eric Gustafsson, CFO
Tel: +46 (0)8-735 55 95
E-mail: info@nextcellpharma.com
Website: www.nextcellpharma.com
LinkedIn: https://www.linkedin.com/company/15255207/
Twitter: https://twitter.com/NextCellPharma

Certified Adviser

The company's shares are listed on the Nasdaq First North Growth Market.
RedEye Noridc Growth AB is the company´s Certified Adviser.

About NextCell Pharma AB

NextCell is a clinical-stage cell therapy company developing the proprietary NXTCL™ platform for the treatment of immune-mediated diseases, with a primary candidate in type 1 diabetes. NXTCL is designed to enable allogeneic cell therapies with controlled immunomodulation, consistent potency and scalable manufacturing. The company's lead program in type 1 diabetes has shown potential to preserve insulin production and slow disease progression for several years after a single treatment. The group also includes the wholly owned subsidiaries NextCell Sverige, NextCell Hong Kong, Cellaviva and QVance. The company was founded in 2014 and is headquartered in Huddinge next to the Karolinska University Hospital.